Drugs Made In America Acquisition II Corp.
DMIINasdaq
$10.08
↓ -0.1%Jul 17 close · end-of-day
Price
1Y↑ +2.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$8.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-48.2%
ROIC
—
Debt / Equity
-0.0
Net Cash
-$102,280.00
Return 1Y
—
Company profile
Drugs Made In America Acquisition II Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses, which we refer to throughout this prospectus as our “initial business combination.” Our executive offices are located in Fort Lauderdale, FL.
- CEO
- Lynn Stockwell
- Sector
- Finance, Insurance, And Real Estate
- Industry
- Trading
- Employees
- 2
- Headquarters
- Florida
Management & directors
- Stockwell LynnCEO and Exe. Chair of Board
- Worman Glenn C.CFO
Roles derived from SEC Form 4 filings.
Earnings
DMII Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2025 |
|---|---|
| Revenue | — |
| Gross profit | — |
| Operating income | -$488,385.00 |
| Net income | $4.2M |
| Diluted EPS | — |
| Operating cash flow | -$1.0M |
| Free cash flow | — |
| Gross margin | — |
| Operating margin | — |
| Net margin | — |
| Line item | Q1 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$59,327.00 | — | -$155,513.00 | — | -$132,030.00 |
| Net income | -$59,327.00 | -$38,073.00 | -$46,158.00 | $4.3M | $4.3M |
| Diluted EPS | — | — | — | — | — |
| Operating cash flow | -$10,044.00 | — | — | — | -$102,503.00 |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
Company news
Feb 24, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-09-26 | Do Catherine | J | 100,000 | — | — | filing |
| 2025-09-26 | Shulgan Myron W. | J | 100,000 | — | — | filing |
| 2025-09-26 | Worman Glenn C.· CFO | J | 100,000 | — | — | filing |
| 2025-09-26 | Stockwell Lynn· CEO and Exe. Chair of Board | Buy | 700,000 | — | — | filing |
| 2025-09-26 | Stockwell Lynn· CEO and Exe. Chair of Board | J | 400,000 | — | — | filing |
| 2025-09-26 | Stockwell Lynn· CEO and Exe. Chair of Board | Sale | 7,966,667 | — | — | filing |
| 2025-09-26 | Drugs Made In America Acquisition II LLC | Buy | 700,000 | — | — | filing |
| 2025-09-26 | Drugs Made In America Acquisition II LLC | J | 400,000 | — | — | filing |
| 2025-09-26 | Drugs Made In America Acquisition II LLC | Sale | 7,966,667 | — | — | filing |
| 2025-09-26 | Prasad Sridhar G. | J | 100,000 | — | — | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.